Targeted Repolarization of Tumor-Associated Macrophages via Imidazoquinoline-Linked Nanobodies

Publikationstyp:
Zeitschriftenaufsatz
Metadaten:
Autoren
  • Evangelia Bolli
  • Maximilian Scherger
  • Sana M Arnouk
  • Ana Rita Pombo Antunes
  • David Strassburger
  • Moritz Urschbach
  • Judith Stickdorn
  • Karen De Vlaminck
  • Kiavash Movahedi
  • Hans Joachim Rader
  • Sophie Hernot
  • Pol Besenius
  • Jo A Van Ginderachter
  • Lutz Nuhn
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000626161500001&DestLinkType=FullRecord&DestApp=WOS_CPL
DOI
10.1002/advs.202004574
eISSN
2198-3844
Externe Identifier
  • Clarivate Analytics Document Solution ID: SE1IO
  • PubMed Identifier: 34026453
Ausgabe der Veröffentlichung
10
Zeitschrift
ADVANCED SCIENCE
Schlüsselwörter
  • cancer immunotherapy
  • drug delivery
  • M2 macrophages
  • nanobodies
  • repolarization
  • TLR 7
  • 8 agonist
  • tumor associated macrophages
Artikelnummer
ARTN 2004574
Datum der Veröffentlichung
2021
Status
Published
Titel
Targeted Repolarization of Tumor-Associated Macrophages via Imidazoquinoline-Linked Nanobodies
Sub types
  • Article
Ausgabe der Zeitschrift
8

Datenquelle: Web of Science (Lite)

Andere Metadatenquellen:
Abstract
<jats:title>Abstract</jats:title><jats:p>Tumor‐associated macrophages (TAMs) promote the immune suppressive microenvironment inside tumors and are, therefore, considered as a promising target for the next generation of cancer immunotherapies. To repolarize their phenotype into a tumoricidal state, the Toll‐like receptor 7/8 agonist imidazoquinoline IMDQ is site‐specifically and quantitatively coupled to single chain antibody fragments, so‐called nanobodies, targeting the macrophage mannose receptor (MMR) on TAMs. Intravenous injection of these conjugates result in a tumor‐ and cell‐specific delivery of IMDQ into MMR<jats:sup>high</jats:sup> TAMs, causing a significant decline in tumor growth. This is accompanied by a repolarization of TAMs towards a pro‐inflammatory phenotype and an increase in anti‐tumor T cell responses. Therefore, the therapeutic benefit of such nanobody‐drug conjugates may pave the road towards effective macrophage re‐educating cancer immunotherapies.</jats:p>
Autoren
  • Evangelia Bolli
  • Maximilian Scherger
  • Sana M Arnouk
  • Ana Rita Pombo Antunes
  • David Straßburger
  • Moritz Urschbach
  • Judith Stickdorn
  • Karen De Vlaminck
  • Kiavash Movahedi
  • Hans Joachim Räder
  • Sophie Hernot
  • Pol Besenius
  • Jo A Van Ginderachter
  • Lutz Nuhn
DOI
10.1002/advs.202004574
eISSN
2198-3844
ISSN
2198-3844
Ausgabe der Veröffentlichung
10
Zeitschrift
Advanced Science
Sprache
en
Online publication date
2021
Datum der Veröffentlichung
2021
Status
Published
Herausgeber
Wiley
Herausgeber URL
http://dx.doi.org/10.1002/advs.202004574
Datum der Datenerfassung
2023
Titel
Targeted Repolarization of Tumor‐Associated Macrophages via Imidazoquinoline‐Linked Nanobodies
Ausgabe der Zeitschrift
8

Datenquelle: Crossref

Abstract
Tumor-associated macrophages (TAMs) promote the immune suppressive microenvironment inside tumors and are, therefore, considered as a promising target for the next generation of cancer immunotherapies. To repolarize their phenotype into a tumoricidal state, the Toll-like receptor 7/8 agonist imidazoquinoline IMDQ is site-specifically and quantitatively coupled to single chain antibody fragments, so-called nanobodies, targeting the macrophage mannose receptor (MMR) on TAMs. Intravenous injection of these conjugates result in a tumor- and cell-specific delivery of IMDQ into MMR<sup>high</sup> TAMs, causing a significant decline in tumor growth. This is accompanied by a repolarization of TAMs towards a pro-inflammatory phenotype and an increase in anti-tumor T cell responses. Therefore, the therapeutic benefit of such nanobody-drug conjugates may pave the road towards effective macrophage re-educating cancer immunotherapies.
Addresses
  • Lab of Cellular and Molecular Immunology Vrije Universiteit Brussel Pleinlaan 2 Brussels 1050 Belgium.
Autoren
  • Evangelia Bolli
  • Maximilian Scherger
  • Sana M Arnouk
  • Ana Rita Pombo Antunes
  • David Straßburger
  • Moritz Urschbach
  • Judith Stickdorn
  • Karen De Vlaminck
  • Kiavash Movahedi
  • Hans Joachim Räder
  • Sophie Hernot
  • Pol Besenius
  • Jo A Van Ginderachter
  • Lutz Nuhn
DOI
10.1002/advs.202004574
eISSN
2198-3844
Externe Identifier
  • PubMed Identifier: 34026453
  • PubMed Central ID: PMC8132149
Funding acknowledgements
  • Deutsche Forschungsgemeinschaft: SFB1066
  • Kom op tegen Kanker:
Open access
true
ISSN
2198-3844
Ausgabe der Veröffentlichung
10
Zeitschrift
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Schlüsselwörter
  • Animals
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Mice
  • Lung Neoplasms
  • Disease Models, Animal
  • Imidazoles
  • Quinolines
  • Membrane Glycoproteins
  • Toll-Like Receptor 7
  • Toll-Like Receptor 6
  • Tumor Microenvironment
  • Single-Domain Antibodies
  • Tumor-Associated Macrophages
  • Mannose Receptor
Sprache
eng
Medium
Electronic-eCollection
Online publication date
2021
Open access status
Open Access
Paginierung
2004574
Datum der Veröffentlichung
2021
Status
Published
Publisher licence
CC BY
Datum der Datenerfassung
2021
Titel
Targeted Repolarization of Tumor-Associated Macrophages via Imidazoquinoline-Linked Nanobodies.
Sub types
  • Research Support, Non-U.S. Gov't
  • research-article
  • Journal Article
Ausgabe der Zeitschrift
8

Files

https://biblio.vub.ac.be/vubirfiles/70534994/advs.202004574.pdf https://europepmc.org/articles/PMC8132149?pdf=render

Datenquelle: Europe PubMed Central

Abstract
Tumor-associated macrophages (TAMs) promote the immune suppressive microenvironment inside tumors and are, therefore, considered as a promising target for the next generation of cancer immunotherapies. To repolarize their phenotype into a tumoricidal state, the Toll-like receptor 7/8 agonist imidazoquinoline IMDQ is site-specifically and quantitatively coupled to single chain antibody fragments, so-called nanobodies, targeting the macrophage mannose receptor (MMR) on TAMs. Intravenous injection of these conjugates result in a tumor- and cell-specific delivery of IMDQ into MMRhigh TAMs, causing a significant decline in tumor growth. This is accompanied by a repolarization of TAMs towards a pro-inflammatory phenotype and an increase in anti-tumor T cell responses. Therefore, the therapeutic benefit of such nanobody-drug conjugates may pave the road towards effective macrophage re-educating cancer immunotherapies.
Autoren
  • Evangelia Bolli
  • Maximilian Scherger
  • Sana M Arnouk
  • Ana Rita Pombo Antunes
  • David Straßburger
  • Moritz Urschbach
  • Judith Stickdorn
  • Karen De Vlaminck
  • Kiavash Movahedi
  • Hans Joachim Räder
  • Sophie Hernot
  • Pol Besenius
  • Jo A Van Ginderachter
  • Lutz Nuhn
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/34026453
DOI
10.1002/advs.202004574
eISSN
2198-3844
Externe Identifier
  • PubMed Central ID: PMC8132149
Ausgabe der Veröffentlichung
10
Zeitschrift
Adv Sci (Weinh)
Schlüsselwörter
  • M2 macrophages
  • TLR 7/8 agonist
  • cancer immunotherapy
  • drug delivery
  • nanobodies
  • repolarization
  • tumor associated macrophages
  • Animals
  • Disease Models, Animal
  • Imidazoles
  • Lung Neoplasms
  • Mannose Receptor
  • Membrane Glycoproteins
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Quinolines
  • Single-Domain Antibodies
  • Toll-Like Receptor 6
  • Toll-Like Receptor 7
  • Tumor Microenvironment
  • Tumor-Associated Macrophages
  • Mice
Sprache
eng
Country
Germany
Paginierung
2004574
PII
ADVS2507
Datum der Veröffentlichung
2021
Status
Published online
Datum, an dem der Datensatz öffentlich gemacht wurde
2022
Titel
Targeted Repolarization of Tumor-Associated Macrophages via Imidazoquinoline-Linked Nanobodies.
Sub types
  • Journal Article
  • Research Support, Non-U.S. Gov't
Ausgabe der Zeitschrift
8

Datenquelle: PubMed

Beziehungen:
Eigentum von

Werkzeuge